Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 612 across all filing types
Latest filing 2026-05-06 AGM Information
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Bulletin from the annual general meeting in Alligator Bioscience AB on 6 May 2026
AGM Information Classification · 100% confidence The document is a press release dated 6 May 2026, summarizing the resolutions adopted at the Annual General Meeting (AGM) of Alligator Bioscience AB. It includes details on adoption of accounts, discharge of liability for board members and CEO, election of board members and auditor, approval of the remuneration report, and authorization regarding share issues. The content is typical of AGM information, focusing on meeting outcomes and decisions rather than full financial statements or detailed reports. The document length is 5666 characters, which is consistent with a detailed AGM bulletin rather than a full annual report or other filings. Therefore, the document fits the category of AGM Information (AGM-R).
2026-05-06 English
Kommuniké från årsstämma den 6 maj 2026 i Alligator Bioscience AB
AGM Information Classification · 95% confidence The document is a press release dated May 6, 2026, summarizing the decisions made at the Annual General Meeting (Årsstämma) of Alligator Bioscience AB. It includes resolutions on approval of financial statements, discharge of board and CEO, election and remuneration of board members and auditors, approval of the remuneration report, and authorization for share issuance. The content is a summary of AGM decisions rather than the full AGM materials or presentations. The document length is 4885 characters, which is relatively short and consistent with a meeting summary or announcement rather than a full report. The document explicitly states it is a communiqué from the AGM, which fits the category of AGM Information (AGM-R). It is not a full Annual Report (10-K), nor an earnings release or other financial report. Therefore, the correct classification is AGM Information (AGM-R).
2026-05-06 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Delårsrapport Januari – mars 2026' which translates to 'Interim Report January – March 2026'. It contains detailed financial data for the first quarter of 2026, including net sales, operating results, cash flow, equity, and per-share data. The text includes management commentary, strategic focus, clinical program updates, and financial key figures for the quarter. The length is substantial (15,000 characters), and it contains substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement of a report or a certification document, so it is not RPA or RNS. Therefore, the correct classification is IR with high confidence. Q1 2026
2026-05-05 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Alligator Bioscience AB (publ) Interim report January – March 2026' and contains detailed financial data for the first quarter of 2026, including net sales, operating profit/loss, cash flow, earnings per share, and other performance measures. It also includes CEO comments, strategic updates, clinical development progress, and governance information. The presence of comprehensive financial statements and substantive financial analysis for a period shorter than a full fiscal year (Q1 2026) clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2026
2026-05-05 English
Ändring av antalet aktier och röster i Alligator Bioscience AB
Share Issue/Capital Change Classification · 85% confidence The document is a press release announcing an increase in the number of shares and voting rights in Alligator Bioscience AB due to the exercise of warrants (TO 14), which constitutes a change in the company’s share capital and number of shares outstanding. This fits the definition of a Share Issue/Capital Change (Code: SHA).
2026-03-31 Swedish
Change in number of shares and votes in Alligator Bioscience AB
Share Issue/Capital Change Classification · 85% confidence The document is a press release by Alligator Bioscience announcing the exercise of warrants and consequent increase in the number of outstanding shares and votes as of 31 March 2026. This constitutes changes in the company’s capital structure (new shares issued via warrant exercise). It is not an earnings release, management change, AGM material, or annual/interim report. It fits the criteria for Share Issue/Capital Change (Code: SHA).
2026-03-31 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.